Current issues in pediatric inflammatory bowel disease-associated arthropathies

World J Gastroenterol. 2014 Jan 7;20(1):45-52. doi: 10.3748/wjg.v20.i1.45.

Abstract

Joint involvement is the most common extraintestinal manifestation in children with inflammatory bowel disease (IBD) and may involve 16%-33% of patients at diagnosis or during follow-up. It is possible to distinguish asymmetrical, transitory and migrating arthritis (pauciarticular and polyarticular) and spondyloarthropathy (SpA). Clinical manifestations can be variable, and peripheral arthritis often occurs before gastrointestinal symptoms develop. The inflammatory intestinal pattern is variable, ranging from sub-clinical inflammation conditions, classified as indeterminate colitis and nodular lymphoid hyperplasia of the ileum, to Crohn's disease or ulcerative colitis. Unlike the axial form, there is an association between gut inflammation and evolution of recurrent peripheral articular disease that coincides with a flare-up of intestinal disease. This finding seems to confirm a key role of intestinal inflammation in the pathogenesis of SpA. An association between genetic background and human leukocyte antigen-B27 status is less common in pediatric than n adult populations. Seronegative sacroiliitis and SpA are the most frequent forms of arthropathy in children with IBD. In pediatric patients, a correct therapeutic approach relies on the use of nonsteroidal antiinflammatory drugs, local steroid injections, physiotherapy and anti-tumor necrosis factor therapy (infliximab). Early diagnosis of these manifestations reduces the risk of progression and complications, and as well as increasing the efficacy of the therapy.

Keywords: Extraintestinal manifestations; Inflammatory bowel disease; Infliximab; Sacroiliitis; Spondyloarthropathy.

Publication types

  • Review

MeSH terms

  • Adolescent
  • Age of Onset
  • Anti-Inflammatory Agents / therapeutic use
  • Child
  • Colitis, Ulcerative / complications
  • Crohn Disease / complications
  • Disease Progression
  • Gastrointestinal Agents / therapeutic use
  • Humans
  • Inflammation Mediators / metabolism
  • Inflammatory Bowel Diseases / complications*
  • Inflammatory Bowel Diseases / diagnosis
  • Inflammatory Bowel Diseases / drug therapy
  • Inflammatory Bowel Diseases / immunology
  • Remission Induction
  • Signal Transduction
  • Spondylarthropathies / diagnosis
  • Spondylarthropathies / drug therapy
  • Spondylarthropathies / etiology*
  • Spondylarthropathies / immunology
  • Treatment Outcome

Substances

  • Anti-Inflammatory Agents
  • Gastrointestinal Agents
  • Inflammation Mediators

Supplementary concepts

  • Pediatric Crohn's disease
  • Pediatric ulcerative colitis